DYSIS Medical

DYSIS Medical is a forward-looking medtech company focused on transforming cervical cancer screening through its innovative computer-aided colposcopy technology. Founded in 2002, the company's FDA-cleared and CE-marked DYSIS Colposcope enhances the accuracy of lesion detection by providing an objective, color-coded map of the cervix. With strong clinical validation from over 5,500 exams, a favorable NICE recommendation in the UK, and adoption in both private practices and public health systems, DYSIS is positioned to improve standard-of-care in a critical area of women's health.

Dynamic Spectral Imaging (DSI) platform that objectively quantifies the dynamics of acetowhitening in cervical tissue during colposcopy, producing a color-coded map (DYSISmap™) to guide biopsy placement and lesion detection.

Total raised: $7M

DYSIS competes with traditional colposcope manufacturers (Leisegang, Olympus) and newer digital/adjunctive technology companies like MobileODT. Its key differentiation is its FDA-cleared and NICE-recommended technology that objectively measures the dynamic acetowhitening process, providing an integrated hardware-software solution designed to improve diagnostic accuracy within the standard clinical workflow.